Uric acid and contrast-induced nephropathy: an updated review and meta-regression analysis

Francesco Pelliccia1, Vincenzo Pasceri2, Giuseppe Patti3, Giuseppe Marazzi4, Giuseppe De Luca5, Gaetano Tanzilli1, Nicola Viceconte1, Giulio Speciale2, Enrico Mangieri1, Carlo Gaudio1

1Department of Cardiovascular Sciences, Sapienza University, Rome, Italy
2Cardiovascular Intervention, San Filippo Neri Hospital, Rome, Italy
3University of L’Aquila, L’Aquila, Italy
4IRCCS San Raffaele Pisana, Rome, Italy
5Division of Cardiology, Azienda Ospedaliera-Universitaria “Maggiore della Carità”, Eastern Piedmont University, Novara, Italy

Abstract

Introduction: Previous studies have suggested a relationship between serum uric acid and contrast-induced nephropathy (CIN).

Aim: We performed an updated review and a meta-regression analysis to assess whether serum uric acid is associated with CIN or there exists any relationship between serum uric acid and other risk factors for CIN.

Material and methods: We searched PubMed, Embase and Cochrane databases and reviewed cited references up to July 31, 2018 to identify relevant studies.

Results: A total of 6,705 patients from 10 clinical studies were included. CIN occurred in 774 of the 6,705 (12%) patients. Baseline uric acid levels were significantly higher in those who developed CIN (6.51 vs. 5.67 mg/dl; 95% CI: 0.55–1.22, p = 0.00001). Comparison of clinical features showed that patients with CIN were significantly older (69 vs. 63 years; p < 0.00001) and more often had diabetes (42% vs. 32%; p = 0.002) and hypertension (67% vs. 59%; p = 0.03). Also, patients who developed CIN had lower hemoglobin (12.5 vs. 13.6 mg/dl; p < 0.00001) and higher levels of baseline creatinine (1.27 vs. 1.01 mg/dl; p < 0.0001), but had similar levels of glycemia, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglyceride. Also, they showed a lower ejection fraction (45% vs. 50%; p < 0.00001). Meta-regression analysis revealed that uric acid related only to age (r = 0.13, p = 0.03).

Conclusions: Our investigation indicates that uric acid is significantly associated with CIN. Uric acid correlated significantly with age only, and not with other major predictors of CIN. Further studies are therefore needed to verify the potential of uric acid to improve CIN risk stratification.

Key words: angiography, contrast-induced nephropathy, percutaneous coronary intervention, uric acid.

Summary

Uric acid relates to the occurrence of contrast-induced nephropathy (CIN), but it remains unclear whether it is merely related to traditional risk factors for CIN or plays an independent predictive role. We performed a meta-analysis and a meta-regression analysis of 10 clinical studies. Baseline uric acid levels were significantly higher in those who developed CIN. Statistical analysis revealed that uric acid correlated significantly with age only, but not with other major predictors of CIN, such as diabetes, hypertension, hemoglobin, creatinine, glycemia, cholesterol, and triglycerides. Uric acid seems to have the potential to improve CIN risk stratification.

Introduction

Contrast-induced nephropathy (CIN) is one of the most common complications of procedures that require the use of contrast media [1, 2]. Contrast-induced nephropathy occurs in up to 25% of patients undergoing diagnostic and/or therapeutic coronary angiography, depending on the presence of known risk factors, such as chronic kidney disease, diabetes mellitus, high dose of
contrast medium, congestive heart failure, and anemia [3, 4]. In recent years, several investigations and some systematic reviews and meta-analyses have shown that hyperuricemia relates to a greater frequency of CIN [5–7]. However, no previous investigation has assessed whether serum uric acid plays an independent role in CIN stratification or is merely related to presenting features and procedural characteristics of patients undergoing elective coronary angiography.

Aim

The aim of the current study was to perform an updated review and a meta-regression analysis in order to assess whether serum uric acid is associated with CIN or there exists any relationship between serum uric acid and other risk factors for CIN.

Material and methods

Study design

This meta-analysis was conducted following current guidelines, including the Cochrane Collaboration and Meta-analysis Of Observational Studies in Epidemiology (MOOSE), and the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) amendment to the Quality of Reporting of Meta-analyses (QUOROM) statement [8–10]. All activities were carried out independently by two reviewers (FP and VP). Divergences were solved after consensus.

Data sources

We searched PubMed, Embase, and Cochrane databases as well as the National Institutes of Health Clinical Trials Registry (www.clinicaltrials.gov) up to July 31, 2018 to identify relevant studies. In addition, we searched the presentations at major cardiovascular scientific sessions including meetings of the American College of Cardiology, American Heart Association and European Society of Cardiology. Additional studies were searched in Google Scholar and Scopus. Editorials and reviews from major medical journals published within the last 5 years were also considered for further information on studies of interest. No language restriction was enforced in order to minimize the risk of publication bias. The following combinations of medical subject heading terms and text words were used: “contrast induced acute kidney injury”, “contrast induced acute renal failure”, “contrast nephropathy”, “contrast induced nephropathy”, “contrast induced nephrotoxicity”, “contrast associated nephropathy”, “contrast associated nephrotoxicity”, and “radiocontrast induced nephropathy”.

Study selection

Retrieved citations were first screened independently by two unblinded investigators (FP and GP) at the title and/or abstract level, with divergences resolved after consensus. Studies were screened in order to identify potentially suitable articles that should be assessed for eligibility as full texts. Notably, a detailed review of study authors, dates, and locations was used to exclude redundancy. Studies with overlapping data were identified, and in cases of apparent serial reporting of a particular patient cohort, only the publication with the largest number of patients was included in the meta-analysis. Only studies published in original articles in peer-reviewed scientific journals were taken into consideration. Studies were then selected according to the following explicit inclusion criteria (all had to be met for inclusion): (i) case series of patients undergoing coronary angiography and/or PCI; (ii) comparison of clinical, laboratory and procedural features between patients with or without post-procedural evidence of CIN; (iii) baseline assessment of uric acid levels.

Data extraction and quality

Analysis was performed at the study level, as databases of the individual patients were not obtained. Data from each study were obtained by two independent reviewers (FP and GP) and entered into a structured spreadsheet. Disagreements were resolved by consensus. Dichotomous variables were extracted in absolute numbers and were recalculated when percentages were reported. Continuous variables were extracted and weighted means for the total study population were calculated. The primary endpoint was baseline uric acid levels in patients with or without CIN. Other endpoints were the differences in clinical, laboratory and procedural features between patients with and without CIN, with special emphasis on renal function. Study validity was tested according to recommendations distinguishing several sources of bias. In order to assess the quality of reporting of the studies, the standard Strengthening the Reporting of Observational Studies in Epidemiology checklist (STROBE) was used [11]. This checklist includes items assessing the study methodology, study type, study population, sample size, sample collection methods, statistical tests, and presentations.

Data analysis and synthesis

All analyses were performed using the Review Manager 5.2.10 software and Comprehensive Meta-analysis Version 3.1. Since heterogeneity of results was expected, the inverse variance method for random effects was used to estimate pooled risk ratios or relative risk for dichotomous variables or mean difference for continuous variables and 95% confidence intervals (CI) [12]. We tested the heterogeneity of the included studies with $Q$ statistics and the extent of inconsistency between results with $I^2$ statistics. Significant heterogeneity was considered present in the case of $I^2 > 50\%$ and/or $p < 0.10$ [13].
However, we did not exclude outliers based on heterogeneity since heterogeneity is expected in meta-analyses of observational studies [14]. Accordingly, we performed a leave-one-out sensitivity analysis for each parameter in order to evaluate the robustness of the results and the impact of each single study on the summary estimate of effect. Briefly, we recalculated pooled estimates multiple times, using a random-effects model, each time with the removal of a single study from the original group. We also performed a sensitivity analysis stratified by sample size to exclude the possibility of overestimating the role of uric acid due to the inclusion of small studies (defined as those with a sample size < 500 patients). Presence of publication bias was estimated by the Rucker test (with arcsine transformation), which is best suited for binary outcomes and funnel plot analysis [15, 16]. Meta-regression analysis was conducted to assess whether there was a direct relationship between levels of uric acid and other variables associated with CIN [17]. Specifically, we performed a weighted random-effects meta-regression regressing uric acid and CIN against the difference of each variable. Results are reported as beta coefficients and two-sided p-values. Statistical significance was set at \( p < 0.05 \) (two-tailed).

### Results

#### Search results

From 2,046 initial citations that were retrieved from multiple databases, a total of 78 articles were analyzed as full reports according to predefined selection criteria. After excluding 68 studies because serum uric acid levels in patients with or without CIN were not reported, 10 investigations were finally deemed as eligible for inclusion in our systematic review (Figure 1) [18–27]. A total of 6,705 patients were included in the 10 studies. Selected studies were published between 2010 and 2015, and included series of patients from North America, Europe, and Asia (Table I). All included patients underwent either coronary angiography or percutaneous coronary intervention (PCI). Quality assessment by STROBE checklist revealed moderate to high quality in all studies (Table II).

---

**Figure 1.** PRISMA diagram of study selection. The flow diagram demonstrates the study selection process in the systematic review and meta-analysis

**Table I. List of included studies**

| Author       | Country | Overall (n) | No CIN (n) | CIN (n) | Coro | PCI | Definition of CIN          |
|--------------|---------|------------|-----------|--------|-----|----|-----------------------------|
| Parkfetrat   | Iran    | 290        | 245       | 45     | Yes | Yes| SCr > 50% or > 0.5 mg/dl    |
| Okino        | China   | 139        | 130       | 9      | Yes | Yes| SCr > 25% or > 0.5 mg/dl    |
| Ma           | China   | 69         | 43        | 26     | Yes | Yes| SCr > 25% or > 0.5 mg/dl    |
| Park         | Korea   | 1247       | 1,196     | 51     | Yes | Yes| SCr > 50% or > 0.5 mg/dl    |
| Kurtul       | Turkey  | 436        | 373       | 63     | Yes | Yes| SCr > 25% or > 0.5 mg/dl    |
| Elbasan      | Turkey  | 835        | 755       | 80     | Yes | Yes| SCr > 25% or > 0.5 mg/dl    |
| Saritemur    | Turkey  | 744        | 651       | 93     | Yes | Yes| SCr > 25% or > 0.5 mg/dl    |
| Ji           | China   | 805        | 497       | 68     | Yes | Yes| SCr > 25% or > 0.5 mg/dl    |
| Barbieri     | Italy   | 1950       | 1,699     | 251    | Yes | Yes| SCr > 25% or > 0.5 mg/dl    |
| Karabulut    | Poland  | 430        | 342       | 88     | Yes | Yes| SCr > 25% or > 0.5 mg/dl    |
| Variable               | Item No. | Recommendation                                                                 | Pakfetrat [18] | Okino [19] | Ma [20] | Park [21] | Kurtul [22] | Elbasan [23] | Saritemur [24] | Ji [25] | Barbieri [26] | Karabulut [27] |
|------------------------|----------|---------------------------------------------------------------------------------|----------------|-----------|---------|-----------|-------------|-------------|----------------|---------|--------------|--------------|
| **Title and abstract** | 1        | (a) Indicate the study’s design with a commonly used term in the title or the abstract | 1              | 1         | 1       | 1         | 1           | 1           | 1             | 1       | 1            | 1            |
|                        |          | (b) Provide in the abstract an informative and balanced summary of what was done and what was found | 1              | 1         | 1       | 1         | 1           | 1           | 1             | 1       | 1            | 1            |
| **Introduction**       | 2        | Explain the scientific background and rationale for the investigation being reported | 1              | 1         | 1       | 1         | 1           | 1           | 1             | 1       | 1            | 1            |
| **Objectives**         | 3        | State specific objectives, including any prespecified hypotheses                | 1              | 1         | 1       | 1         | 1           | 1           | 1             | 1       | 1            | 1            |
| **Methods**            | 4        | Present key elements of study design early in the paper                          | 1              | 1         | 0       | 1         | 0           | 1           | 0             | 1       | 1            | 1            |
| Study design           |          |                                                                                   |                |           |         |           |             |              |               |         |              |              |
| Setting                | 5        | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection | 1              | 1         | 1       | 1         | 1           | 1           | 1             | 1       | 1            | 1            |
| **Participants**       | 6        | (a) Cohort study – Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up Case-control study – Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls Cross-sectional study – Give the eligibility criteria, and the sources and methods of selection of participants | 1              | 1         | 1       | 1         | 1           | 1           | 1             | 1       | 1            | 1            |
|                        |          | (b) Cohort study – For matched studies, give matching criteria and number of exposed and unexposed Case-control study – For matched studies, give matching criteria and the number of controls per case | 1              | 0         | 0       | 0         | 1           | 1           | 0             | 1       | 0            | 0            |
| Variables              | 7        | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable | 1              | 1         | 0       | 1         | 1           | 1           | 1             | 1       | 0            | 0            |
| Data sources/measurement | 8        | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group | 1              | 1         | 1       | 1         | 1           | 1           | 1             | 1       | 1            | 1            |
| Variable          | Item No. | Recommendation                                                                 | Pakfetrat [18] | Okino [19] | Ma [20] | Park [21] | Kurtul [22] | Elbasan [23] | Saritemur [24] | Ji [25] | Barbieri [26] | Karabulut [27] |
|-------------------|----------|---------------------------------------------------------------------------------|----------------|------------|---------|-----------|------------|-------------|----------------|--------|--------------|---------------|
| Bias              | 9        | Describe any efforts to address potential sources of bias                      | 1              | 1          | 0       | 1         | 0          | 1           | 0            | 1      | 0            | 0             |
| Study size        | 10       | Explain how the study size was arrived                                         | 0              | 0          | 0       | 0         | 0          | 0           | 0            | 0      | 0            | 0             |
| Quantitative variables | 11       | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why | 1              | 1          | 0       | 1         | 1          | 1           | 1            | 1      | 1            | 1             |
| Statistical methods | 12       | (a) Describe all statistical methods, including those used to control for confounding | 1              | 1          | 1       | 1         | 1          | 1           | 1            | 1      | 1            | 1             |
|                   |          | (b) Describe any methods used to examine subgroups and interactions            | 1              | 1          | 1       | 1         | 1          | 1           | 1            | 1      | 1            | 1             |
|                   |          | (c) Explain how missing data were addressed                                    | 1              | 1          | 1       | 1         | 1          | 1           | 1            | 1      | 1            | 1             |
|                   |          | (d) **Cohort study** – If applicable, explain how loss to follow-up was addressed |                  |             |         |           |            |              |              |        |              |                |
|                   |          | **Case-control study** – If applicable, explain how matching of cases and controls was addressed |                  |             |         |           |            |              |              |        |              |                |
|                   |          | **Cross-sectional study** – If applicable, describe analytical methods taking account of sampling strategy |                  |             |         |           |            |              |              |        |              |                |
|                   |          | (e) Describe any sensitivity analyses                                          | 1              | 1          | 1       | 1         | 1          | 1           | 0            | 0      | 0            | 1             |
| Participants      | 13*      | (a) Report numbers of individuals at each stage of study, eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed | 1              | 1          | 1       | 1         | 1          | 1           | 1            | 1      | 1            | 1             |
|                   |          | (b) Give reasons for non-participation at each stage                            | 1              | 1          | 0       | 0         | 0          | 0           | 0            | 0      | 0            | 0             |
|                   |          | (c) Consider use of a flow diagram                                             | 1              | 0          | 1       | 1         | 1          | 0           | 1            | 0      | 0            | 1             |
| Descriptive data  | 14*      | (a) Give characteristics of study participants (eg, demographic, clinical, social) and information on exposures and potential confounders | 1              | 1          | 0       | 1         | 1          | 1           | 1            | 0      | 1            |                |
|                   |          | (b) Indicate number of participants with missing data for each variable of interest | 1              | 1          | 1       | 1         | 1          | 1           | 1            | 1      | 1            |                |
|                   |          | (c) **Cohort study** – Summarise follow-up time (eg, average and total amount) |                  |             |         |           |            |              |              |        |              |                |
| Variable            | Item No. | Recommendation                                                                 | Pakfetrat [18] | Okino [19] | Ma [20] | Park [21] | Kurtul [22] | Elbasan [23] | Saritemur [24] | Ji [25] | Barbieri [26] | Karabulyut [27] |
|---------------------|----------|---------------------------------------------------------------------------------|----------------|------------|---------|-----------|-------------|--------------|----------------|---------|-------------|-----------------|
| Outcome data        | 15*      | *Cohort study* – Report numbers of outcome events or summary measures over time |                 |            |         |           |             |              |               |         |             |                 |
|                     |          | *Case-control study* – Report numbers in each exposure category, or summary measures of exposure | 1              | –          | 1        | 1         | 1           | –            | –             | 1       | 1           | 1                |
|                     |          | *Cross-sectional study* – Report numbers of outcome events or summary measures    | –              | 1          | –        | –         | –           | –            | 1             | –       | –           | –                |
| Main results        | 16       | (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included. | 1              | 1          | 0        | 1         | 0           | 0            | 0             | 0       | 0           | 0                |
|                     |          | (b) Report category boundaries when continuous variables were categorized        | 0              | 0          | 0        | 0         | 0           | 0            | 1             | 0       | 0           | 0                |
|                     |          | (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period | 0              | 0          | 0        | 0         | 0           | 1            | 0             | 0       | 0           | 0                |
| Other analyses      | 17       | Report other analyses done, eg analyses of subgroups and interactions, and sensitivity analyses | 1              | 1          | 1        | 1         | 1           | 1            | 1             | 1       | 1           | 1                |
| Discussion          |          |                                                                                  |                |            |         |           |             |              |               |         |             |                 |
| Key results         | 18       | Summarise key results with reference to study objectives                         | 1              | 1          | 1        | 1         | 1           | 1            | 1             | 1       | 1           | 1                |
| Limitations         | 19       | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias | 1              | 1          | 0        | 0         | 0           | 1            | 0             | 0       | 0           | 0                |
| Interpretation      | 20       | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence | 1              | 1          | 1        | 1         | 1           | 1            | 1             | 1       | 1           | 1                |
| Generalisability    | 21       | Discuss the generalisability (external validity) of the study results            | 1              | 1          | 1        | 1         | 1           | 1            | 1             | 1       | 1           | 1                |
| Other information   |          |                                                                                  |                |            |         |           |             |              |               |         |             |                 |
| Funding             | 22       | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based | 0              | 0          | 0        | 0         | 0           | 1            | 0             | 1       | 0           | 0                |
| Total scores        |          |                                                                                  | 28             | 26         | 19       | 25         | 24           | 24           | 23             | 25      | 19          | 24               |
Definition of CIN

CIN was defined variously in the studies. Most studies described CIN as an increase in serum creatinine levels of more than 25% or 0.5 mg/dl above the baseline 48–72 h following intravascular contrast medium administration [19, 20, 22, 24–27]. CIN was defined according to the RIFLE criteria by Pakfetrat et al. [18] as an increase in serum creatinine of ≥ 0.5 mg/dl or ≥ 50% over baseline within 7 days by Park et al. [21], and as an increase ≥ 25% in creatinine by Elbasan et al. [23].

Primary end-point

CIN occurred in 774 of the 6,727 (11.5%) patients. Frequency of CIN ranged between 4.1% and 37.7%. Baseline uric acid levels were significantly higher in those who developed CIN 6.51 (95% CI: 6.23–6.78) vs. 5.67 (95% CI: 5.25–6.09) mg/dl; mean difference: 0.88, 95% CI 0.55–1.22, p < 0.00001; I² = 83%, p < 0.00001 (Table III; Figure 2).

Factors associated with CIN

Comparison of clinical features at referral showed that patients who experienced CIN were significantly older (69 (95% CI: 64–72) vs. 63 (95% CI: 59–67) years; mean difference: 5.25, 95% CI: 3.19–7.32, p < 0.00001; I² = 81%, p < 0.00001), more often had diabetes (42% vs. 32%; risk ratio: 0.70, 95% CI: 0.56–0.88, p = 0.002; I² = 81%, p < 0.00001) and hypertension (67% vs. 59%; risk ratio: 0.84, 95% CI: 0.72–0.98, p = 0.03; I² = 81%, p < 0.00001), with no difference in prevalence of smoking and hyperlipidemia (Table III; Figure 3). With respect to laboratory findings at baseline, patients who developed CIN had lower hemoglobin (12.5 (95% CI: 12.1–12.9) vs. 13.6 (95% CI: 13.2–13.9) mg/dl; mean difference: 1.02, 95% CI: 0.61–1.42, p < 0.00001; I² = 71%, p = 0.0002) and higher levels of baseline creatinine (1.27 (95% CI: 1.07–1.43) vs. 1.01 (95% CI: 0.86–1.16) mg/dl; mean difference: 0.22, 95% CI: 0.11–0.32, p < 0.00001; I² = 94%, p = 0.00001), but had similar levels of glucose, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglyceride (Table IV; Figure 3). Also, they showed a lower ejection fraction (45% (95% CI: 42–47) vs. 50% (95% CI: 46–53); mean difference: 4.89, 95% CI 2.77–7.01, p < 0.00001; I² = 71%, p = 0.0002) (Table V; Figure 4).

Meta-regression analysis

Meta-regression (Table VI) revealed that uric acid, apart from a relationship with age (r = −0.75, p = 0.02), was not associated with major risk factors for CIN, i.e. diabetes, hypertension, ejection fraction, hemoglobin and baseline creatinine (Figures 5 and 6).

Sensitivity analysis and publication bias

The leave-one-out analysis showed that the pooled results were not influenced by any single trial. In addi-
tion, excluding studies with large (> 500 patients) or small (< 500 patients) sample sizes did not change results of the meta-analyses. Rucker's test did not suggest publication bias (p = 0.77 for CIN). Funnel plot analysis showed no asymmetry suggesting a significant risk of publication bias, and that the end-points did not depend on the size of the studies (Figure 7).

Discussion

Serum uric acid is an underestimated and under-reported parameter in studies dealing with cardiac angiography and interventional procedures. Our study is the first meta-regression on this topic, showing that uric acid does not correlate with major predictors of CIN, with the exception of age, thus indicating that it might constitute a novel independent predictor to be included in CIN risk stratification.

Serum uric acid is the final product of purine metabolism, and uric acid levels depend on many factors, including diet, drug therapy, presence of kidney disease, increased purine turnover, etc. Hyperuricemia is associated with urate deposition, leading to gout arthritis and kidney stones [28]. Uric acid may also have a role in acute renal failure. Indeed, several studies have suggested a significant association between hyperuricemia and the development and progression of kidney disease and renal function impairment [29–31]. Uric acid can also impair endothelial function, as it inactivates nitric oxide, i.e. endothelium-derived relaxing factor, and inhibits release of nitric oxide from endothelial cells [32]. The relationship between hyperuricemia and renal failure may be helpful for understanding the association between uric acid and CIN. However, to date, limited information is available on the effects of contrast media on uric acid metabolism. Two pioneer investigations in the 1970s showed that contrast agents have a uricosuric effect with enhanced renal tubular secretion of uric acid and a possible nephrotoxic effect [33, 34]. In addition, uric acid is associated with other factors that play a role in the pathogenesis of CIN, such as enhanced synthesis of reactive oxygen species, activation of the renin–angiotensin–aldosterone system, an increase in endothelin-1, and inhibition of the nitric oxide system [35].

Various patient- and procedure-related risk factors may contribute to CIN. Pre-existing renal insufficiency and diabetes mellitus are the two main patient-related risk factors. In a retrospective review of 938 patients with stable renal insufficiency, the overall incidence of CIN was 6.1%, while the incidence was 4.4%, 10.5% and 10.0% in patients whose eGFR was 45–60, 30–45 and ≤ 30 ml/min, respectively [36]. In the present study, baseline factors significantly associated with CIN included age, creatinine, lower hemoglobin, lower ejection fraction, diabetes and hypertension. It may be hypothesized that uric acid might be a marker for the presence of one or more of these well-known risk factors. However, our meta-regression analysis showed only a moderate significant association between uric acid and age, as expected, while other risk factors, including baseline creatinine, diabetes and hypertension, did not show any relationship with uric acid. These results suggest an independent association between uric acid and CIN, not mediated by other risk factors. It is worth noting the lack of associa-

| Study            | No CIN Mean | SD | Total | CIN Mean | SD | Total | Mean difference IV, random, 95% CI | Year | Mean difference IV, random, 95% CI |
|------------------|-------------|----|-------|----------|----|-------|-----------------------------------|------|-----------------------------------|
| Parkfettrat      | 6.2         | 1.6| 245   | 6.1      | 2  | 45    | 0.10 (–0.52, 0.72)                | 2010 |                                   |
| Okino            | 6.6         | 1.6| 130   | 7.3      | 2.7| 9     | –0.70 (–2.49, 1.09)               | 2010 |                                   |
| Ma               | 4.81        | 1.15| 43    | 6.75     | 1.99| 26    | –1.94 (–2.78, –1.10)              | 2010 |                                   |
| Park             | 5.12        | 1.54| 196   | 6.51     | 2.23| 51    | –1.39 (–2.01, –0.77)              | 2011 |                                   |
| Kurtul           | 5.49        | 1.53| 373   | 6.53     | 1.76| 63    | –1.04 (–1.50, –0.58)              | 2014 |                                   |
| Elbasan          | 5.1         | 0.9 | 755   | 6.2      | 0.9 | 80    | –1.10 (–1.31, –0.89)              | 2014 |                                   |
| Sanitemur        | 4.89        | 1.32| 651   | 6.09     | 2.01| 93    | –1.20 (–1.62, –0.78)              | 2014 |                                   |
| Ji               | 6.02        | 1.75| 497   | 6.78     | 1.96| 68    | –0.76 (–1.25, –0.27)              | 2015 |                                   |
| Barbieri         | 6.35        | 1.79| 1699  | 6.6      | 1.81| 251   | –0.25 (–0.49, –0.01)              | 2015 |                                   |
| Karabulut        | 6.08        | 2.1 | 342   | 6.83     | 1.9 | 88    | –0.75 (–1.21, –0.29)              | 2015 |                                   |

Total (95% CI) 5931 774 –0.88 (–1.22, –0.55)

Heterogeneity: t² = 0.21, χ² = 51.56, df = 9 (p < 0.00001), I² = 83%
Test for overall effect: Z = 5.15 (p < 0.00001)

Figure 2. Forest plot of risk ratios for contrast-induced nephropathy according to uric acid. Markers represent point estimates of risk ratios, marker size represents study weight. Horizontal bars indicate 95% confidence intervals.
**Figure 3.** Forest plot of risk ratios for contrast-induced nephropathy according to age (A), diabetes (B) and hypertension (C). Markers represent point estimates of risk ratios, marker size represents study weight. Horizontal bars indicate 95% confidence intervals.
### Table IV. Laboratory findings at baseline

| Author     | Hemoglobin [g/l] | Glycemia [mg/dl] | Total cholesterol [mg/dl] | LDL cholesterol [mg/dl] | HDL cholesterol [mg/dl] | Triglyceride [mg/dl] |
|------------|------------------|------------------|---------------------------|-------------------------|-------------------------|---------------------|
|            | No CIN (X)       | CIN (X)          | No CIN (X)                | CIN (X)                 | No CIN (X)              | CIN (X)             |
| Parkfetrat | NA               | NA               | 125 (63)                  | 131 (54)                | 186 (48)                | 389 (30)            |
| Okino      | NA               | NA               | NA                        | NA                      | NA                      | NA                  |
| Ma         | NA               | NA               | 107 (99–136)              | 125 (106–143)           | 195 (40)                | 203 (50)            |
| Park       | 13.5 (1.9)       | 11.9 (2.1)       | 118 (39)                  | 145 (73)                | NA                      | NA                  |
| Kurtul     | 14.1 (1.9)       | 12.7 (2.1)       | 158 (87)                  | 158 (78)                | 191 (49)                | 176 (61)            |
| Elbasan    | 13.6 (1.9)       | 12.2 (2.2)       | 146 (79)                  | 159 (86)                | 190 (46)                | 191 (40)            |
| Saritemur  | 13.6 (1.8)       | 12.9 (2.2)       | NA                        | NA                      | 113 (36)                | 116 (42)            |
| Ji         | 13.3 (1.8)       | 12.6 (2.2)       | NA                        | NA                      | 158 (43)                | 158 (50)            |
| Barbieri   | 13.2 (NA)        | 12.7 (NA)        | 127 (NA)                  | 134 (NA)                | 159 (NA)                | 91 (NA)             |
| Karabulut  | NA               | NA               | NA                        | NA                      | NA                      | NA                  |

CIN – contrast-induced nephropathy, HDL – high-density lipoprotein, LDL – low-density lipoprotein.

### Table V. Pre- and post-procedural findings

| Author     | Contrast media [ml] | Baseline eGFR | Baseline creatinine [mg/dl] | Post-creatinine [mg/dl] | LV ejection fraction (%) |
|------------|---------------------|---------------|-----------------------------|-------------------------|--------------------------|
|            | No CIN (X)          | CIN (X)       | No CIN (X)                  | CIN (X)                 | No CIN (X)               | CIN (X)             |
| Parkfetrat | 62 (45)             | 84 (73)       | 82 (36)                     | 67 (16)                 | 0.90 (0.30)              | 1.10 (0.20)         |
| Okino      | 177 (131)           | 148 (74)      | 40 (13)                     | 32 (11)                 | 1.43 (0.60)              | 1.67 (0.43)         |
| Ma         | 160 (46)            | 181 (53)      | NA                          | NA                      | NA                       | NA                  |
| Park       | 306 (132)           | 359 (159)     | 86 (33)                     | 45 (26)                 | 0.81 (0.26)              | 1.52 (0.71)         |
| Kurtul     | NA                  | NA            | 72 (20)                     | 50 (18)                 | 1.06 (0.27)              | 1.37 (0.38)         |
| Elbasan    | 197 (79)            | 253 (124)     | NA                          | NA                      | 0.91 (0.22)              | 0.96 (0.26)         |
| Saritemur  | 256 (84)            | 286 (72)      | 90 (23)                     | 70 (23)                 | 0.86 (0.20)              | 1.03 (0.40)         |
| Ji         | NA                  | NA            | 65 (25)                     | 50 (30)                 | 0.94 (0.37)              | 1.36 (0.79)         |
| Barbieri   | 217 (NA)            | 291 (NA)      | NA                          | NA                      | 1.18 (NA)                | 1.17 (NA)           |
| Karabulut  | NA                  | NA            | 69 (21)                     | 64 (23)                 | 1.05 (0.27)              | 1.13 (0.25)         |
| Overall    | 196                 | 208           | 72                          | 54                      | 1.01                     | 1.27                |

CIN – contrast-induced nephropathy, CKD – chronic kidney disease, eGFR – estimated glomerular filtration rate.
### Study  No CIN   CIN  Mean difference Year  Mean difference

| Mean  | SD  | Total | Mean  | SD  | Total | IV, random, 95% CI | IV, random, 95% CI |
|-------|-----|-------|-------|-----|-------|-------------------|-------------------|
| Park  | 13.5| 1.9   | 1196  | 11.9| 2.1   | 51                | 1.60 (1.01, 2.19) | 2011               |
| Kurtul| 14.1| 1.9   | 373   | 12.7| 2.1   | 63                | 1.40 (0.85, 1.95) | 2014               |
| Elbasan| 13.6| 1.9   | 755   | 12.2| 2.2   | 80                | 1.40 (0.90, 1.90) | 2014               |
| Saritemur| 13.6| 1.8   | 651   | 12.9| 2.2   | 93                | 0.70 (0.23, 1.17) | 2014               |
| Ji    | 13.3| 1.8   | 497   | 12.6| 2.2   | 68                | 0.70 (0.15, 1.25) | 2015               |
| Barbieri| 13.2| 1.8   | 1699  | 12.7| 1.7   | 251               | 0.50 (0.27, 0.73) | 2015               |
| Karabulut| 0   | 0     | 342   | 0   | 0     | 88                | Not estimable     | 2015               |

Total (95% CI)   5171 606 1.02 (0.61, 1.42)

### Heterogeneity:
- $t^2 = 0.19$, $\chi^2 = 24.19$, df = 5 ($p = 0.0002$), $\text{I}^2 = 79$
- Test for overall effect: $Z = 4.93$ ($p < 0.00001$)

### Study  No CIN   CIN  Mean difference Year  Mean difference

| Mean  | SD  | Total | Mean  | SD  | Total | IV, random, 95% CI | IV, random, 95% CI |
|-------|-----|-------|-------|-----|-------|-------------------|-------------------|
| Parkfetrat | 0.9 | 0.3   | 245   | 1.1 | 0.2   | 45                | –0.20 (–0.27, –0.13) | 2010               |
| Okino  | 1.43| 0.6   | 130   | 1.67| 0.43  | 9                 | –0.24 (–0.54, 0.06) | 2010               |
| Park   | 0.81| 0.26  | 1196  | 1.52| 0.71  | 51                | –0.71 (–0.91, –0.51) | 2011               |
| Kurtul | 1.06| 0.27  | 373   | 1.37| 0.38  | 63                | –0.31 (–0.41, –0.21) | 2014               |
| Elbasan| 0.91| 0.22  | 755   | 0.96| 0.26  | 80                | –0.05 (–0.11, 0.01) | 2014               |
| Saritemur| 0.86| 0.2   | 651   | 1.03| 0.4   | 93                | –0.17 (–0.25, –0.09) | 2014               |
| Ji     | 0.94| 0.37  | 497   | 1.36| 0.79  | 68                | –0.42 (–0.61, –0.23) | 2015               |
| Barbieri| 1.18| 0.3   | 1699  | 1.17| 0.2   | 251               | 0.01 (–0.02, –0.04) | 2015               |
| Karabulut| 1.05| 0.27  | 342   | 1.13| 0.25  | 88                | –0.08 (–0.14, –0.02) | 2015               |

Total (95% CI)   5888 748 –0.22 (–0.32, –0.11)

### Heterogeneity:
- $t^2 = 0.02$, $\chi^2 = 128.25$, df = 8 ($p < 0.00001$), $\text{I}^2 = 94$
- Test for overall effect: $Z = 4.15$ ($p < 0.00001$)

### Study or subgroup  No CIN   CIN  Weight  Mean difference Year  Mean difference

| Mean  | SD  | Total | Mean  | SD  | Total | (%) | IV, random, 95% CI | IV, random, 95% CI |
|-------|-----|-------|-------|-----|-------|-----|-------------------|-------------------|
| Parkfetrat | 49  | 13    | 245   | 43  | 17    | 45   | 9.4              | 6.00 (0.77, 11.23) | 2010               |
| Ma     | 56  | 10    | 43    | 47  | 10    | 26   | 10.2             | 9.00 (4.13, 13.87) | 2010               |
| Park   | 55  | 13    | 1196  | 47  | 14    | 51   | 12.6             | 8.00 (4.09, 11.91) | 2011               |
| Kurtul | 47  | 10    | 373   | 40  | 10    | 63   | 16.3             | 7.00 (4.33, 9.67)  | 2014               |
| Elbasan| 46  | 10    | 755   | 44  | 8     | 80   | 18.7             | 2.00 (0.11, 3.89)  | 2014               |
| Saritemur| 48  | 8     | 651   | 44  | 9     | 93   | 18.6             | 4.00 (2.07, 5.93)  | 2014               |
| Karabulut| 48  | 15    | 342   | 47  | 14    | 88   | 14.3             | 1.00 (–2.33, 4.33) | 2015               |

Total (95% CI)   5931 774 4.89 (2.77, 7.01)

### Heterogeneity:
- $t^2 = 5.34$, $\chi^2 = 20.81$, df = 6 ($p = 0.002$), $\text{I}^2 = 71$
- Test for overall effect: $Z = 4.51$ ($p < 0.00001$)

**Figure 4.** Forest plot of risk ratios for contrast-induced nephropathy according to hemoglobin (A), creatinine (B) and ejection fraction (C). Markers represent point estimates of risk ratios, marker size represents study weight. Horizontal bars indicate 95% confidence intervals.
tion between uric acid and baseline levels of creatinine, which is the most important single risk factor for CIN [1]. Measuring serum uric acid levels before PCI might be a useful method for assessing the risk of developing CIN and short-term clinical outcomes. The difference in uric acid levels between patients with or without CIN was 0.88 mg/dl, suggesting that even a moderate increase in uric acid levels can be of clinical relevance in this setting. Noteworthy, our findings are in agreement with previous work by Shacham et al., who performed a retrospective analysis of 1,372 consecutive patients with acute myocardial infarction and found that uric acid was an independent predictor of CIN [37]. Interestingly, these authors noted that for every 1-mg/dl increase in the uric acid concentration, the adjusted risk for CIN increased by 46% [37].

There are some intrinsic limitations of this study as a result of the study design. Major limitations include the case-control design and the relatively small number of studies included in the meta-analysis, which might affect the main results and the results of the meta-regression analysis. Another limitation is the high heterogeneity among the studies. Indeed, studies selected for this meta-analysis differ in multiple aspects (i.e. sample size, definition or frequency of CIN, etc). However, in order to evaluate the stability of the results, we performed a 'leave-one-out' sensitivity analysis and were able to show that omission of each study did not change the overall results. We acknowledge the fact that assessment of serum uric acid is affected by the hydration status. Also, the results of the present study should not lead to disregarding the well-recognized role of diabetes, hypertension and renal function, which have been previously demonstrated to be major predictors of CIN. Our review focused only on studies in which contrast was administered for a coronary procedure; therefore, the risk models reviewed might not be applied to other procedures, such as intravenous contrast-enhanced computed tomography, computed tomography angiography, and non-coronary angiography. Publication bias always remains a concern because this investigation could analyze only published data, although funnel

| Parameter      | $\beta$ | 95% CI       | P-value |
|----------------|---------|--------------|---------|
| Age            | 0.13    | 0.01–0.26    | 0.03    |
| Hemoglobin     | −1.06   | −2.10–0.01   | 0.06    |
| Diabetes       | 0.04    | −0.01–0.08   | 0.07    |
| Hypertension   | 0.02    | −0.03–0.07   | 0.40    |
| Creatinine     | 0.71    | −1.78–3.20   | 0.58    |
| Ejection fraction | −0.06 | −0.28–0.16  | 0.62    |

Table VI. Meta-regression weighted by total sample size of studies

Figure 5. Meta-regression of the effects of age, hypertension and diabetes on baseline uric acid levels. Each circle size represents a study highlighted by its weight in the analysis
plot analysis did not show any evidence of publication bias. A possible drawback lies in the study-level setting, thus lacking the precision and flexibility of a patient-level work, which would have enabled more detailed analyses. Although individual patient data would have provided more detailed information, patient-level and study-level meta-analyses are often in agreement, and thus our findings should be consistent with future prospective studies in individual patients. Although the case control design of selected studies does not allow uric acid to be defined as an independent risk factor, our meta-regression analysis does not suggest a correlation of uric acid with other risk factors, with the exception of age.

Conclusions

This large study-level meta-analysis and meta-regression indicates that uric acid is significantly associated with CIN. Uric acid correlated significantly with age only, but not with other major predictors of CIN. These results should be considered hypothesis-generating findings that may warrant further investigation to verify the potential role of uric acid to improve CIN risk stratification.

Conflict of interest

The authors declare no conflict of interest.

References

1. Mehran R, Nikolsky E. Contrast-induced nephropathy: definition, epidemiology, and patients at risk. Kidney Int Suppl 2006; 69: S11e5.
2. Gleeson TG, Bulugahapitiya S. Contrast-induced nephropathy. Am J Roentgenol 2004; 183: 1673-89.
3. Gami AS, Garovic VD. Contrast nephropathy after coronary angiography. Mayo Clin Proc 2004; 79: 211-9.
4. Lepor NE. Radiocontrast nephropathy: the dye is not cast. Rev Cardiovasc Med 2000; 1: 43-54.

5. Zuo T, Jiang L, Mao S, et al. Hyperuricemia and contrast-induced acute kidney injury: a systematic review and meta-analysis. Int J Cardiol 2016; 224: 286-94.

6. Xu X, Hu J, Song N, et al. Hyperuricemia increases the risk of acute kidney injury: a systematic review and meta-analysis. BMC Nephrology 2017; 18: 27.

7. Kanbay M, Solak Y, Afar B. Serum uric acid and risk for acute kidney injury following contrast. Angiology 2017; 68: 132-44.

8. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283: 2008-12.

9. Moher D, Eastwood S, et al. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of reporting of meta-analyses. Lancet 1999; 354: 1896-900.

10. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions; explanation and elaboration. BMJ 2009; 339: b2700.

11. von Elm E, Altman DG, Mosteller F. Heterogeneity in meta-analyses. BMJ 2003; 327: 589-624.

12. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-60.

13. Colditz GA, Burdick E, Mosteller F. Heterogeneity in meta-analysis of data from epidemiologic studies: a commentary. Am J Epidemiol 1995; 142: 371-82.

14. van Houwelingen HC, Arends LR, Stijnen T. Advanced methods in meta-analysis: multivariate approach and meta-regression. Stat Med 2002; 21: 589-624.

15. Rucker G, Schwarzer G, Carpenter J. Arcsine test for publication bias. Biometrics 1994; 50: 1088-746-63.

16. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088-101.

17. Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted? Stat Med 2002; 21: 1559-73.

18. Pakfetrat M, Nikoo MH, Malekmakan L, et al. Risk factors for contrast-related acute kidney injury according to risk, injury, failure, loss, and end-stage criteria in patients with coronary interventions. Iran J Kidney Dis 2010; 4: 116-22.

19. Okino S, Fukuzawa S, Inagaki M, et al. Hyperuricemia as a risk factor for progressive renal insufficiency after coronary intervention in patients with chronic kidney disease. Cardiovasc Interv Ther 2010; 25: 105-11.

20. Ma G, Yu D, Cai Z, et al. Contrast-induced nephropathy in post-menopausal women undergoing percutaneous coronary intervention for acute myocardial infarction. Tohoku J Exp Med 2010; 221: 211-9.

21. Park SH, Shin WY, Lee EY, et al. The impact of hyperuricemia on in-hospital mortality and incidence of acute kidney injury in patients undergoing percutaneous coronary intervention. Circ J 2011; 75: 692-7.

22. Kurtul A, Duran M, Yarlioglu M, et al. Association between N-terminal pro-brain natriuretic peptide levels and contrast-induced nephropathy in patients undergoing percutaneous coronary intervention for acute coronary syndrome. Clin Cardiol 2014; 37: 485-92.

23. Elbasan Z, Şahin DY, Gür M, et al. Contrast-induced nephropathy in patients with ST elevation myocardial infarction treated with primary percutaneous coronary intervention. Angiology 2014; 65: 37-42.

24. Sarıtemur M, Türkeli M, Kalkan K, et al. Relation of uric acid and contrast-induced nephropathy in patients undergoing primary percutaneous coronary intervention in the ED. Am J Emerg Med 2014; 32: 119-23.

25. Ji L, Su X, Qin W, et al. Novel risk score of contrast-induced nephropathy after percutaneous coronary intervention. Nephrology 2015; 20: 544-51.

26. Barbieri L, Verdoia M, Schaffer A, et al. Uric acid levels and the risk of contrast induced nephropathy in patients undergoing coronary angiography or PCI. Nutr Metab Cardiovasc Dis 2015; 25: 181-6.

27. Karabulut A, Şahin I, Ilker Avci I, et al. Impact of serum alkaline phosphatase level on the pathophysiologic mechanism of contrast-induced nephropathy. Kardiol Pol 2014; 72: 977-82.

28. Richette P, Bardin T. Gout. Lancet 2010; 375: 318-28.

29. Ficociello LH, Rosolowsky ET, Niewczas MA, et al. High-normal serum uric acid increases risk of early progressive renal function loss in type 1 diabetes: results of a 6-year follow-up. Diabetes Care 2010; 33: 1337-43.

30. Hovind P, Rossing P, Tarnow L, et al. Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes: an inception cohort study. Diabetes 2009; 58: 1668-71.

31. Chen JH, Chuang SY, Chen HI, et al. Serum uric acid level as an independent risk factor for all-cause, cardiovascular, and ischemic stroke mortality: a Chinese cohort study. Arthritis Rheum 2009; 61: 225-32.

32. Ho WJ, Tsai WP, Yu KH, et al. Association between endothelial dysfunction and hyperuricaemia. Rheumatology 2010; 49: 1929-34.

33. Postlethwaite AE, Kelley WN. Uricosuric effect of radiocontrast agents. A study in man of four commonly used preparations. Ann Intern Med 1971; 74: 845-52.

34. Mudge GH. Uricosuric action of cholecystographic agents: possible nphrotoxicity. N Engl J Med 1971; 284: 929-34.

35. Kang DH, Nakagawa T. Uric acid and chronic renal disease: possible implication of hyperuricemia on progression of renal disease. Semin Nephrol 2005; 25: 43-9.

36. Murakami R, Hayashi H, Sugizaki K, et al. Contrast-induced nephropathy in patients with renal insufficiency undergoing contrast-enhanced MDCT. Eur Radiol 2012; 22: 2147-52.

37. Shacham Y, Gal-Oz A, Flint N, et al. Serum uric acid levels and renal impairment among ST-segment elevation myocardial infarction patients undergoing primary percutaneous intervention. Cardiorenal Med 2016; 6: 191-7.